29 March 2010 - UK-based biopharmaceutical company Antisoma plc
(LON: ASM) announced today that the planned interim analysis of data from the ATTRACT-1 phase III trial of ASA404 in previously untreated non-small cell lung cancer (NSCLC) has shown that continuation of the trial would be futile, as there is little or no prospect of demonstrating a survival benefit with ASA404 in this setting.
18 March 2010 - UK biotechnology company Antisoma plc
(LON: ASM) said today it has initiated a randomised, controlled, multi-territory, Phase IIb trial of AS1411 in patients with acute myeloid leukemia (AML).
Biopharmaceutical company Antisoma plc
(LSE:ASM) (USOTC:ATSMY) reported on Wednesday that results of the company's phase II trial of AS1411 as a second-line treatment for metastatic renal cell carcinoma (RCC; kidney cancer) provide further evidence that the drug has anti-cancer activity.